Preventice Solutions  

2600 Eagan Woods Drive
suite 200
- eagan,  MN  55121

United States
http://www.preventicesolutions.com
  • Booth: 3031

Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services, connecting patients threatened by cardiac arrhythmias. Creating revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian family.


 Press Releases

  • Minneapolis, September 1, 2020 – Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), announced today it received the 2020 Frost & Sullivan Global Remote Cardiac Monitoring Company of the Year Award. As published by Frost & Sullivan, this award reflects a company’s leadership among its industry and non-industry peers and “translates into superior performance in demand generation, brand development, and competitive position that serve as the foundation of a company’s future success,” stated Kaustubh Savant, Senior Industry Analyst at Frost & Sullivan.

    “We are honored to be selected by Frost & Sullivan to receive this award for our commitment to delivering innovation and clinical value to patients and healthcare providers in the global remote cardiac monitoring market,” said Jon P. Otterstatter, Chief Executive Officer of Preventice Solutions. “Our commitment remains to advance a comprehensive portfolio of monitoring technologies and services that offer physicians the ability to diagnose and manage patients based on real-time clinical data, and for patients the reassurance that they can receive the care and oversight of their cardiac performance without interrupting their daily activities.”

    Frost & Sullivan justified its recognition of Preventice Solutions as the Global Company of the Year recipient in the remote cardiac monitoring market due to the following factors:

    • Preventice Solutions offers a comprehensive portfolio of highly accurate and sensitive BodyGuardian® family of remote monitors. The BodyGuardian® MINI is the world's smallest truly waterproof, replaceable, and repositionable monitor. With the longest battery and enhanced capabilities, the system enables quick, timely, rich, and detailed insights into patients' heart condition for risk management and optimized care while allowing patients to follow their daily routine.
    • Preventice Solutions highly accurate and validated BeatLogic® deep learning algorithms detect, classify, and interpret variations in heart rhythm data collected through the BodyGuardian technology. The robust algorithms set new industry benchmarks in accuracy and provide intuitive clinical decision making from voluminous real-time ECG data.
    • Preventice’s total solution enables risk mitigation, prevents hospitalization and readmission, improves physician efficiency, and bolsters timely intervention. With multiple business models that include traditional and flexible solutions, Preventice Solutions efficiently supports physician practices' variable needs and requirements.

    For the Company of the Year Award, Frost & Sullivan analysts independently evaluate several criteria under visionary leadership and performance (addressing unmet needs, visionary scenarios, implementation of best practices, blue ocean strategy, and financial performance) and customer impact (price/performance value, customer purchase, ownership and service experience, and brand equity). Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

    Transforming Preventive Cardiovascular Care through Remote Cardiac Monitoring
    Preventice Solutions has over a decade of experience as a trusted service and technology partner that provides monitoring for millions of patients, supports thousands of practices nationwide, and leverages its proprietary BeatLogic® deep learning platform. In May 2020, Preventice Solutions was the first to publish in the Heart Rhythm Journal and showed that BeatLogic® outperformed a leading industry standard algorithm on Afib in the MIT-BIH Atrial Fibrillation Database (AFDB) library and MIT-BIH Ventricular Ectopic Beats (VEB) classification.

    Preventice Solutions recently launched BodyGuardian® MINI, the first single holistic solution for the patient, practice, and provider that covers all four cardiac monitoring modalities, including short and long-term Holter, cardiac event monitoring, and mobile cardiac telemetry. Using ECG Insight® , physicians can gain instant access to the raw data within telemetry reports to improve timely diagnosis remotely. Provided wirelessly through Preventice’s cloud-based infrastructure, these new technologies have been well received by healthcare professionals who appreciate the simplicity of inventory management, enhanced experience, and refined service.

    According to the World Health Organization, cardiovascular disease is the leading cause of mortality, accounting for nearly 17.9 million annual global deaths. In the United States, studies show that approximately 47% of sudden cardiac deaths happen outside the hospital environment, indicating that early signs of heart ailments often go unnoticed.

    About Preventice Solutions
    Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. Preventice Solutions’ wearable portfolio includes the PatientCare Platform and BodyGuardian® family. For more information, please visit www.preventicesolutions.com.

  • Minneapolis, July 15th, 2020 – Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), today announced that it has raised $137M in a Series B financing to accelerate investment in salesforce expansion, technology and product innovation and further development of clinical evidence supporting its flagship solution. The financing was led by new investor Vivo Capital with participation by another new investor Novo Holdings A/S as well as significant support from existing investors including Merck Global Health Innovation Fund, Boston Scientific and Samsung Catalyst Fund.

    “Vivo is extremely pleased to partner with Jon Otterstatter and his management team, Merck Global Health Innovation Fund, Boston Scientific, Samsung Catalyst Fund and Novo Holdings to provide expansion capital to accelerate the tremendous growth the company has achieved in the cardiac monitoring space over the past few years,” said Joe Siletto, Managing Director of Vivo Capital, who has also joined Preventice’s board of directors. “Preventice’s team has leveraged its software industry experience to design a scalable, mobile and cloud-based solution and establish the company as a leader in the rapidly growing remote monitoring space.”

    "We are pleased to have Vivo Capital and Novo Holdings as new investors, and with this funding we are poised to further accelerate our growth," said Jon P. Otterstatter, Chief Executive Officer of Preventice Solutions. "We are setting a new standard for monitoring of cardiac arrythmia patients. Our robust and growing success with physicians and payers accentuates the compelling value proposition of using novel technology to improve diagnosis, while also increasing the efficiency of healthcare delivery.”

    Over the past few years, Preventice’s growth trajectory in remote cardiac monitoring has increased significantly, driven by the rollout of its new BodyGuardian® MINI family of monitors and its PatientCare Platform. PatientCare, a cloud-based subscription platform, provides best-in-class solutions for all constituents in the cardiac monitoring ecosystem including patients, physicians and hospital networks.

    Preventice has over a decade of experience as a trusted service and technology partner providing monitoring for millions of patients, supporting thousands of practices nationwide and leveraging its proprietary BeatLogic® deep learning platform. In May 2020, Preventice was the first to publish in the Heart Rhythm Journal and show that BeatLogic® outperformed the leading gold standard algorithms on Afib in the MIT Atrial Fibrillation Database (AFDB) library and MIT Ventricular Ectopic Beats (VEB) classification.

    Preventice recently launched BodyGuardian® MINI, the first, single holistic solution for the patient, practice and provider covering all four cardiac monitoring modalities including short and long-term Holter, cardiac event monitoring and mobile cardiac telemetry. Using ECG Insight®, physicians can gain instant access to the raw data within telemetry reports, helping to improve timely diagnosis. Provisioned wirelessly via its cloud-based infrastructure, these new technologies have been well received by healthcare professionals, who appreciate the simplicity of inventory management, enhanced experience and refined service.

    In addition, the company’s proven PatientCare Platform and its discrete data and electronic medical record integration expertise, not only provide leading clinical accuracy and reporting but also enable Integrated Delivery Networks (IDN) to leverage Preventice’s world class solutions. Designed around flexibility, Preventice allows physicians and IDNs to tailor their cardiac monitoring to meet their specific service needs and best match payer requirements.

    About Vivo Capital
    Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. Vivo has approximately $4.3 billion in assets under management, invested in over 260 public and private companies worldwide. The firm is headquartered in Palo Alto, California, with additional offices in Asia. The Vivo team consists of more than 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. Vivo provides a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Across all fund strategies, Vivo invests broadly in the healthcare sector including biotechnology, pharmaceuticals, medical devices, and healthcare services.

    About Novo Holdings A/S
    Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: http://www.novoholdings.dk

    About Preventice Solutions
    Preventice Solutions is a leader in digital healthcare solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias with their care teams. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian® family of monitors. For more information please visit: www.preventicesolutions.com

  • Minneapolis, May 7, 2020 – Preventice Solutions announced the publication of real-world data further validating BeatLogic® deep learning models designed to detect and classify multiple levels of data on heart rhythms gathered using BodyGuardian® remote cardiac monitoring technology. The technology leverages deep learning models trained to interpret electrocardiogram (ECG) data gathered while patients are wearing remote technology to monitor their heart rhythm while they go about their daily activities away from their physician’s office. This study is the first to demonstrate deep learning capabilities capable of performing both beat and rhythm classification and was published online in the May 2020 edition of the journal, Heart Rhythm.

    “Advanced technologies offer us the capability of managing a significant amount of near real-time data to uncover important insights in the care of patients,” said Dr. Hamid Ghanbari, MD, MPH, a cardiovascular electrophysiologist at the University of Michigan and author on the manuscript. “This analysis continues to validate that it is feasible to train the deep learning models to closely monitor and interpret multiple levels of signals with a high level of reliability. Most important, this allows physicians to effectively utilize the volumes of data to guide their care and allow them to spend more time focusing on the patient.”

    The recently published analysis utilized ECG recordings from the BodyGuardian® remote monitoring platform. BeatLogic® deep learning models were trained to detect and classify rhythms using the ECGs. Key outcomes of the study:

    Beat detection sensitivity and positive predictive value were 99.84 percent and 99.78 percent, respectively. Both results outperformed the “state-of-the-art” algorithm across every measure for beat, rhythm detection and classification.
    BeatLogic® outperformed all other algorithms on MIT Ventricular Ectopic Beats (VEB) classification.
    On the MIT-BIH Atrial Fibrillation Database (AFDB) dataset, BeatLogic® outperformed all other algorithms on Afib in the MIT AFDB library.

    “The potential for remote monitoring technologies continues to grow and it means we have to offer technologies that can manage the significant amount of data that exists for each patient,” said Emily Benner, Executive Vice President Research and Product Development, Preventice Solutions. “We continue to focus our investment on technology advances that empower physicians with data that is accessible and usable as they are making clinical decisions for the individual patient. This latest advance in deep learning supports the ability to interpret multiple levels of data that are relevant to each patient experience and to do so with a high level of accuracy.”

    Remote cardiac monitoring has been shown to provide clinical decision support for physicians and while algorithms have helped in capturing and even prioritizing the data, the interpretation has been left up to the physician. Yet, the immense burden of interpreting the necessary amount of data requires a critical amount of physician time for every patient they monitor. Deep learning has the potential to improve this process.

    The study utilized training data from 20,932 individual records. The final training dataset consisted of more than 780 hours of ECG from 11,008 unique patients. The training annotations were created, annotated and adjudicated by a team of certified technicians.

    ECG for the gold standard validation dataset was selected from real world data mined from the over 500 deidentified unique BodyGuardian® patients. Comprehensive annotation was performed by a senior team of certified ECG technicians and adjudicated by three board certified electrophysiologists. Validation was also performed using the MIT-BIH Arrhythmia Database (MIT-BIH) and the MIT Atrial Fibrillation Database (AFDB). Dr. Ghanbari has received consultation fees from Preventice for advising on remote monitoring technology and services.

    About the BodyGuardian® Remote Monitoring System
    The BodyGuardian® Remote Monitoring System includes integration of the BodyGuardian® family of monitors and additional third-party sensors, the BodyGuardian® Connect smartphone and the PatientCare Platform. The system utilizes deep learning to remotely recognize AF and integrate data into the electronic health record. Patients wear cardiac monitors, which feed near real-time data into the cloud-based platform that physicians can access. Growing clinical use resulting from increased incidence of cardiac disease and a rising aging population forces a greater reliance on algorithms in order to provide high-quality reporting in a timely manner. These factors are amplified in the case of mobile cardiac telemetry (MCT), where ECG is streamed directly to data processing centers, annotated, and may be used to quickly alert clinicians of potentially critical cardiac events.

    About Preventice Solutions
    Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias with their care teams. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian® family of monitors. For more information please visit www.preventicesolutions.com.


 Products

  • BodyGuardian® MINI
    BodyGuardian® MINI is the first fully waterproof-submersible arrhythmia monitor and differentiates from other commercial Holter monitors in its small design and up to 16 days battery life that is among the longest in the industry....

  • BodyGuardian® MINI is the first fully waterproof-submersible arrhythmia monitor and differentiates from other commercial Holter monitors in its small design and up to 16 days battery life that is among the longest in the industry. The product is indicated for monitoring arrhythmias in both pediatric and adult patients.

    The repositionable monitor has multiple placement options; it can be used either as a patch or attached to a traditional lead set to get three channel signals that provide more data. The patch optimizes patient comfort and wearability. It is conveniently movable, re-applicable, and replaceable during the study period without compromising on data collection or requiring additional clinic visits. The adhesive used by Preventice does not require significant skin preparation and offers an easy and comfortable wearing experience.

    The compact size allows placing the monitor on the center of the chest to capture the P-wave data optimally, providing high clinical yield. The ultra-small, lightweight system enables up continuous ECG measurements, conveniently and quickly transferable to a physician in an easy-to-read, data-rich report. The monitor design and ease-of-use enable patients to follow an unhindered daily routine during water sports or swimming, bolstering compliance without interrupting cardiac monitoring.

  • BodyGuardian® MINI PLUS
    BodyGuardian® MINI PLUS is one device for all remote monitoring modalities running as a short or long-term Holter, cardiac event monitor, or mobile cardiac telemetry monitor....

  • BodyGuardian® MINI PLUS is one device for all remote monitoring modalities running as a short or long-term Holter, cardiac event monitor, or mobile cardiac telemetry monitor. Available in a configuration with either one or two wearable monitors, the MINI PLUS includes a specially provisioned smartphone to collect ECG data in near real-time.

    Data is available throughout the monitoring period for mobile cardiac telemetry. Also, the electronic diary catalogs symptoms on the smartphone for easy patient entry and automatic transmission to experts for summarizing symptoms and arrhythmia correlations in results

    In the COVID-19 era, Patients can now have access to monitoring right from their homes, without having to visit a clinic or hospital, and physicians have smarter actionable data at their fingertips to provide timely, informed clinical decisions. Using the ECG Insight® feature for mobile cardiac telemetry, physicians can see all rhythms a patient is having and generate data requests for a specific data section for medical records or treatment reasons.

  • PatientCare
    Priority during this time of uncertainty is to ensure physicians have the tools they need to take care of patients — and that patients have access to the highest quality of care. When your needs change, your system should too....

  • ENABLING THE CLINIC OF TOMORROW

    Priority during this time of uncertainty is to ensure physicians have the tools they need to take care of patients — and that patients have access to the highest quality of care. We know that patients with cardiovascular diseases are among those most at risk from the virus, with significantly higher mortality rates. When your needs change, your system should too.

    The PatientCare cloud-based, HIPAA-compliant self-managed platform works in tandem with the wireless monitors and transmits near real-time data, 24 hours a day, seven days a week, 365 days a year. It enables physicians, researchers, and care teams to collect, analyze, interpret, and manage patient data securely without requiring multiple patient site visits throughout the study.

    To assist physicians in understanding the real-time monitoring data for every patient and assist clinical decision support, Preventice developed the BeatLogic® deep learning algorithm platform to detect, classify, and interpret variations in heart rhythm data collected through the BodyGuardian® technology. The company's recently published study in the May 2020 edition of the journal Heart Rhythm establishes the BeatLogic® algorithm’s unparalleled accuracy and capabilities in classifying both beat and rhythm.